JPH03161443A - コール酸又はそのナトリウム塩からなる強心剤 - Google Patents
コール酸又はそのナトリウム塩からなる強心剤Info
- Publication number
- JPH03161443A JPH03161443A JP30359789A JP30359789A JPH03161443A JP H03161443 A JPH03161443 A JP H03161443A JP 30359789 A JP30359789 A JP 30359789A JP 30359789 A JP30359789 A JP 30359789A JP H03161443 A JPH03161443 A JP H03161443A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- sodium salt
- formula
- cholic
- cardiotonic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 22
- 239000000496 cardiotonic agent Substances 0.000 title claims abstract description 12
- 235000019416 cholic acid Nutrition 0.000 title abstract description 26
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 title abstract description 10
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 title abstract description 9
- 239000004380 Cholic acid Substances 0.000 title abstract description 9
- 229960002471 cholic acid Drugs 0.000 title abstract description 9
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 20
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 18
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims abstract description 16
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims abstract description 15
- 108010007979 Glycocholic Acid Proteins 0.000 claims abstract description 13
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940099347 glycocholic acid Drugs 0.000 claims abstract description 13
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 239000000829 suppository Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000007796 conventional method Methods 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000006188 syrup Substances 0.000 abstract description 3
- 235000020357 syrup Nutrition 0.000 abstract description 3
- 210000001367 artery Anatomy 0.000 abstract description 2
- 230000000916 dilatatory effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
- 239000002812 cholic acid derivative Substances 0.000 description 17
- 150000001842 cholic acids Chemical class 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 9
- 230000008602 contraction Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- -1 Sodium glycocholic acid Cholic acid salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30359789A JPH03161443A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる強心剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30359789A JPH03161443A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる強心剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03161443A true JPH03161443A (ja) | 1991-07-11 |
| JPH0541604B2 JPH0541604B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Family
ID=17922917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30359789A Granted JPH03161443A (ja) | 1989-11-21 | 1989-11-21 | コール酸又はそのナトリウム塩からなる強心剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03161443A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248152A (zh) * | 2018-11-02 | 2019-01-22 | 河北医科大学第二医院 | 一种治疗肝胆疾病的药物制剂及其制备方法 |
-
1989
- 1989-11-21 JP JP30359789A patent/JPH03161443A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248152A (zh) * | 2018-11-02 | 2019-01-22 | 河北医科大学第二医院 | 一种治疗肝胆疾病的药物制剂及其制备方法 |
| CN109248152B (zh) * | 2018-11-02 | 2021-01-12 | 河北医科大学第二医院 | 一种治疗肝胆疾病的药物制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0541604B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60131547T2 (de) | Abführende zusammensetzungen | |
| DE2711493C2 (enrdf_load_stackoverflow) | ||
| Mulder et al. | Complete Repair of a Syndrome of Congenital Defects Involving the Abdominal Wall, Sternum, Diaphragm, Pericardium, and Heart; Excision of Left: Ventricular Diverticulum | |
| EP0010156B1 (de) | 6-Arylpyridazin-3-one, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung | |
| DE69830154T2 (de) | Pharmazeutische zusammensetzungen | |
| DE3310556A1 (de) | Verwendung von prostaglandinanalogen | |
| JPS58203911A (ja) | プロスタグランジン類似化合物を有効成分として含有する細肪障害治療剤 | |
| JPH03161443A (ja) | コール酸又はそのナトリウム塩からなる強心剤 | |
| JPH03161442A (ja) | コール酸又はそのナトリウム塩からなる脳代謝改善剤 | |
| DE3311922A1 (de) | Antifibrotische mittel | |
| US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
| JPS6355489B2 (enrdf_load_stackoverflow) | ||
| EP1191935B1 (en) | Treatment or prevention of coronary graft vasospasm | |
| Ericsson et al. | Compression of the trachea by an anomalous innominate artery | |
| CA2022323C (en) | Excretion of potassium ion by prostanoic acid derivatives | |
| JPH0446124A (ja) | 抗潰瘍剤 | |
| DK145420B (da) | Analogifremgangsmaade til fremstilling af alfa-methyl-5-benzoyl-2-thiophenacetatet af tromethamin | |
| Leeds | The tetralogy of Fallot in older persons up to the fifth decade: Results of subclavian-pulmonary anastomosis with a five-to ten-year follow-up | |
| DE1792811C2 (de) | "Arzneimittel mit koronargefäßerweiternder Wirkung" | |
| KR0178696B1 (ko) | 간보호 및 간장질환 치료용 의약조성물 | |
| JPH04210644A (ja) | 高血圧症治療剤 | |
| Schott | Circulatory failure due to vitamin B deficiency | |
| DE69529070T2 (de) | Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv | |
| Chandler et al. | Benign duodeno-colonic Fistula | |
| Warren et al. | Recent advances in pharmacology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |